[go: up one dir, main page]

DK1931697T3 - IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse - Google Patents

IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse

Info

Publication number
DK1931697T3
DK1931697T3 DK06815733.8T DK06815733T DK1931697T3 DK 1931697 T3 DK1931697 T3 DK 1931697T3 DK 06815733 T DK06815733 T DK 06815733T DK 1931697 T3 DK1931697 T3 DK 1931697T3
Authority
DK
Denmark
Prior art keywords
antagonists
methods
present
receptor
antagonize
Prior art date
Application number
DK06815733.8T
Other languages
English (en)
Inventor
Steven D Levin
Mark W Rixon
Zeren Gao
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK1931697T3 publication Critical patent/DK1931697T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK06815733.8T 2005-09-28 2006-09-28 IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse DK1931697T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72116205P 2005-09-28 2005-09-28
US75379405P 2005-12-22 2005-12-22
US77202206P 2006-02-10 2006-02-10
US78224706P 2006-03-14 2006-03-14
PCT/US2006/037950 WO2007038703A2 (en) 2005-09-28 2006-09-28 Il-17a and il-17f antagonists and methods of using the same

Publications (1)

Publication Number Publication Date
DK1931697T3 true DK1931697T3 (da) 2010-11-08

Family

ID=37672342

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06815733.8T DK1931697T3 (da) 2005-09-28 2006-09-28 IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse

Country Status (17)

Country Link
US (1) US20070238658A1 (da)
EP (1) EP1931697B1 (da)
JP (1) JP2009510093A (da)
KR (1) KR20080056241A (da)
AT (1) ATE481424T1 (da)
AU (1) AU2006294511B2 (da)
BR (1) BRPI0616589A2 (da)
CA (1) CA2621623A1 (da)
CY (1) CY1110856T1 (da)
DE (1) DE602006016965D1 (da)
DK (1) DK1931697T3 (da)
EA (1) EA015351B1 (da)
HK (1) HK1112927A1 (da)
IL (1) IL189726A0 (da)
PL (1) PL1931697T3 (da)
PT (1) PT1931697E (da)
WO (1) WO2007038703A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1641822E (pt) 2003-07-08 2013-08-27 Genentech Inc Polipéptidos heterólogos il-17 a/f e suas utilizações terapêuticas
MXPA06014465A (es) * 2004-06-10 2007-05-16 Zymogenetics Inc Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
WO2006012627A2 (en) 2004-07-23 2006-02-02 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
WO2007133250A2 (en) 2005-10-31 2007-11-22 Austin Gurney Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7612041B2 (en) 2005-11-23 2009-11-03 Acceleron Pharma Inc. Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
JP2009520479A (ja) * 2005-12-22 2009-05-28 ラボラトワール セローノ ソシエテ アノニム 溶解性il−17rc変異体及びそれらの使用
AU2007300393B2 (en) * 2006-02-10 2012-05-31 Zymogenetics, Inc. Soluble IL-17RCx4 and methods of using in inflammation
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR101526613B1 (ko) 2007-02-01 2015-06-26 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
CN101679497A (zh) * 2007-03-26 2010-03-24 津莫吉尼蒂克斯公司 可溶性il-17ra/rc融合蛋白以及相关方法
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
US8460647B2 (en) 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
EP2171449A2 (en) * 2007-06-20 2010-04-07 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
LT2340031T (lt) 2008-08-14 2019-08-12 Acceleron Pharma Inc. Gdf gaudyklės, skirtos naudoti anemijos gydymui
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
AU2010232693B2 (en) 2009-03-30 2016-04-21 Acceleron Pharma Inc. BMP-ALK3 antagonists and uses for promoting bone growth
CN104840944A (zh) 2009-06-08 2015-08-19 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ, インコーポレイテッド 切断型ActRIIB−Fc融合タンパク質
NZ598351A (en) * 2009-08-27 2014-08-29 Covagen Ag Il-17 binding compounds and medical uses thereof
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
AU2010322011B2 (en) 2009-11-17 2016-03-31 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド frizzled結合剤およびその使用
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
EP3964224A1 (en) 2012-11-02 2022-03-09 Celgene Corporation Activin-actrii antagonists and uses for use in treating renal disease
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN103992400B (zh) * 2014-05-29 2017-01-04 江苏吴中医药集团有限公司苏州中凯生物制药厂 重组人血管内皮抑素的复性液及其制备、使用方法
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
HRP20230504T1 (hr) 2014-12-03 2023-09-15 Celgene Corporation Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma
US20210340214A1 (en) * 2018-08-29 2021-11-04 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
AU1158297A (en) 1995-11-09 1997-05-29 Zymogenetics Inc. Production of gad65 in methylotrophic yeast
IL128073A0 (en) 1996-07-17 1999-11-30 Zymogenetics Inc Transformation of pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
JP2002514049A (ja) 1996-07-17 2002-05-14 ザイモジェネティクス,インコーポレイティド ピヒア・メタノリカの栄養要求性突然変異体の製造
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
ATE365800T1 (de) * 1998-05-15 2007-07-15 Genentech Inc Therapeutische verwendungen von il-17 homologe polypeptide
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
US20030199041A1 (en) * 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
DE60034564T2 (de) * 1999-07-07 2007-12-27 Zymogenetics, Inc., Seattle Menschlicher cytokinrezeptor
US20040197306A1 (en) * 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
AU2001274920A1 (en) * 2000-05-24 2001-12-03 Schering Corporation Mammalian receptor proteins; related reagents and methods
WO2002058717A2 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US20040097447A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of interleukin 22 receptor expression
WO2004019866A2 (en) * 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
PT1641822E (pt) * 2003-07-08 2013-08-27 Genentech Inc Polipéptidos heterólogos il-17 a/f e suas utilizações terapêuticas
MXPA06014465A (es) 2004-06-10 2007-05-16 Zymogenetics Inc Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.

Also Published As

Publication number Publication date
PL1931697T3 (pl) 2011-03-31
BRPI0616589A2 (pt) 2011-06-28
HK1112927A1 (en) 2008-09-19
US20070238658A1 (en) 2007-10-11
EA200800956A1 (ru) 2008-12-30
EA015351B1 (ru) 2011-06-30
CY1110856T1 (el) 2015-06-10
IL189726A0 (en) 2008-08-07
KR20080056241A (ko) 2008-06-20
EP1931697B1 (en) 2010-09-15
EP1931697A2 (en) 2008-06-18
WO2007038703A3 (en) 2007-07-05
CA2621623A1 (en) 2007-04-05
WO2007038703A2 (en) 2007-04-05
JP2009510093A (ja) 2009-03-12
AU2006294511A1 (en) 2007-04-05
ATE481424T1 (de) 2010-10-15
DE602006016965D1 (de) 2010-10-28
PT1931697E (pt) 2010-12-06
AU2006294511B2 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
DK1931697T3 (da) IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
MX2009010273A (es) Proteinas de fusion il-17ra/rc solubles y metodos relacionados.
DE602004028347D1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
WO2007106769A3 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
IL192950A0 (en) Soluble il-17rcx4 and methods of using in inflammation
NO20070153L (no) Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
HK1110333A1 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
DK1576011T3 (da) Inhibering af IL-17 produktion
WO2009082624A3 (en) Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2008133684A8 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
DK1572967T3 (da) IL-1-receptorbaserede antagonister og fremgangsmåder til fremstilling og anvendelse deraf
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
WO2007147019A3 (en) Il-17 and il-23 antagonists and methods of using the same
NO20061906L (no) Terapeutisk middel for mesoteliom
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
WO2008134659A3 (en) Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
ATE419845T1 (de) Il-8-rezeptor-antagonisten
NO20072514L (no) Loselig ZcytoR21, anti-ZcytoR21-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
CY1113088T1 (el) Il-22 για την προληψη λοιμωδων νοσηματων
EA200700023A1 (ru) Разрыхляющаяся при пероральном приёме фармацевтическая композиция, содержащая рисперидон
NO20055228L (no) Stamceller med okt sensitivitet for SDF-1 og fremgangsmate for fremstilling og anvendelse derav